MOG (Rat, Mouse, 35-55)

Product overview
Catalog Number
PPH08-0718
Sequence
H-Met-Glu-Val-Gly-Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys-OH
Target
Encephalitogenic Determinant. Central nervous system development; positive regulation of MyD88-dependent toll-like receptor signaling pathway; cell adhesion
Description
The MOG peptide fragment 35-55 (Myelin Oligodendrocyte Glycoprotein Peptide Fragment 35-55) induces experimental autoimmune encephalomyelitis in rodents. A single injection of this peptide produces a relapsing-remitting neurologic disease (multiple sclerosis, MS) with extensive plaque-like demyelination. Other experiments show that immunization with MOG (35-55) suppresses spontaneous regeneration of dopaminergic neurons injured with MPTP (a neurotoxin). MOG: Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell- cell communication. Defects in MOG are the cause of narcolepsy type 7 (NRCLP7). Neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed. Belongs to the immunoglobulin superfamily. BTN/MOG family. 10 isoforms of the human protein are produced by alternative splicing.
Category
Catalog peptides, Biologically Active Peptides
Product Properties
Quantity

1mg, 5mg
Storage

Shipped at 4°C. Store at -20°C for one year.
Purity

> 95%
Source

Synthetic
Forma appearance

Lyophilized powder
  • For research use only
  • Not for use in diagnostic procedures

€114,00 – €510,00 Tax excluded
Contact us to request price here
Register to buy peptides
Contact us